ArticleFrontiers in immunology2025
Performance of eight serum cytokine/chemokine biomarkers in discriminating between active and latent tuberculosis infection in Ghana.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Physiological stage-dependent effects ofFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The existing Interferon γ release assay (IGRA) tests for TB infection, lacks utility in discriminating between active TB (ATB) and latent TB infection (LTBI). This study evaluated the potential of eight serum cytokines/chemokines in differentiating LTBI from ATB and as a surrogate marker for TB treatment response. Methods: We quantified and compared the serum levels of pro-inflammatory cytokines (TNF-α, IFN-γ, IL-12p70, IL-17A, Granzyme B) and anti-inflammatory cytokines (IL-10, IL-6, IL-4) among LTBI, ATB, and healthy controls using the Human Magnetic Luminex™ 200 system. Serum cytokine/chemokine levels were also assessed at four timepoints before and during TB treatment. Results: Among ATB cases, there were twice as many males (69%) as females (30%), with infectivity spanning a wide age range. IFN-γ, IL-6, IL-10, IL-4, and IL-17A levels were higher in LTBI compared to ATB. IL-12p70 was found to be a good discriminant between ATB and LTBI (21-fold increase in ATB compared to LTBI, p < 0.05) but it did not have a good predictive potential for treatment (follow up). The predictive potential of TNF-α, IL-6, IL-10, IFN-γ, IL-4, IL-17A, Granzyme B and IL-12p70 to differentiate between ATB and LTBI using AUROC was 57%, 98 %, 91%, 100%, 100%, 97%, 66% and 100% respectively. Discussion: These findings confirm reports from other studies in different settings that LTBI and ATB express differential cytokine profiles that can be exploited as diagnostic biomarkers. Of note, the quantitative estimation of IL-12p70 may serve as a valuable marker for monitoring disease progression and treatment success in tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.